Erratum: The effect of azoximer bromide (polyoxidonium®) in patients hospitalized with coronavirus disease (covid-19): An open-label, multicentre, interventional clinical study ((2021) 10 (2021-11-1) DOI: 10.7573/dic.2020-11-1)

S. V. Efimov; N. V. Matsiyeuskaya; O. V. Boytsova

ArticleOPEN ACCESS

Erratum: The effect of azoximer bromide (polyoxidonium®) in patients hospitalized with coronavirus disease (covid-19): An open-label, multicentre, interventional clinical study ((2021) 10 (2021-11-1) DOI: 10.7573/dic.2020-11-1)

Drugs in Context

DOI: 10.7573/DIC.2021-5-2

0Citations

6Readers

Abstract

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): An open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1.

Cite

CITATION STYLE

APA

Efimov, S. V., Matsiyeuskaya, N. V., & Boytsova, O. V. (2021). Erratum: The effect of azoximer bromide (polyoxidonium®) in patients hospitalized with coronavirus disease (covid-19): An open-label, multicentre, interventional clinical study ((2021) 10 (2021-11-1) DOI: 10.7573/dic.2020-11-1). Drugs in Context. Bioexcel Publishing LTD. https://doi.org/10.7573/DIC.2021-5-2

Erratum: The effect of azoximer bromide (polyoxidonium®) in patients hospitalized with coronavirus disease (covid-19): An open-label, multicentre, interventional clinical study ((2021) 10 (2021-11-1) DOI: 10.7573/dic.2020-11-1)

Abstract

Cite

Register to see more suggestions